Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 24, 2025
Daily News
March 24, 2025
- MHLW Panel Discusses Ways to Promote Clinical Trials
March 24, 2025
- Fair or Unfair? PMP Return Applied for First Time in Off-Year Revision
March 24, 2025
- PMDA Issues Guidance for Pediatric Drug Development
March 24, 2025
- Strattera Stock Expected to Run Out as Lilly's Talks with Regulators Drag On
March 24, 2025
- FPMAJ Maps Out Planned Activities for FY2025
March 24, 2025
- Mitsubishi Seeks Uplizna Nod for IgG4-Related Disease in Japan
March 24, 2025
- Keytruda Filed for Perioperative Use for Head and Neck Cancer in Japan
March 24, 2025
- Departing Employee Stole Personal Data on 5,200 People: MSD
March 24, 2025
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…